AG
EWTX icon

Algert Global’s Edgewise Therapeutics EWTX Stock Holding History

Algert Global’s Portfolio EWTX Stock Details EWTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.92M Buy
47,240
+14,720
+45% +$507K 0.02% 841
2026
Q1 		$1.02M Buy
+32,520
New +$938K 0.02% 862
2025
Q4 		– Sell
-40,963
Closed -$664K – 1196
2025
Q3 		$664K Buy
40,963
+6,240
+18% +$88.5K 0.01% 893
2025
Q2 		$455K Buy
+34,723
New +$501K 0.01% 955
2025
Q1 		– Sell
-110,259
Closed -$2.94M – 1223
2024
Q4 		$2.94M Buy
110,259
+100,859
+1,073% +$3.21M 0.07% 472
2024
Q3 		$251K Buy
+9,400
New +$187K 0.01% 1032

Other funds holding EWTX

O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.72B AUM 106.92% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Algert Global's EWTX Position: Q2 2026 in Review

Algert Global increased its Edgewise Therapeutics (EWTX) stake by 45% in Q2 2026, buying an estimated $507K and bringing the position to 47,240 shares worth $1.92M. The position accounts for 0.02% of the portfolio, ranked #841.

Algert Global first reported a position in EWTX in Q3 2024 and has held it in 6 quarters since. The position peaked at $2.94M in Q4 2024. 223 funds tracked by Wall St. Rank hold EWTX as of Q2 2026.

  • Algert Global held 47,240 shares of Edgewise Therapeutics worth $1.92M as of Q2 2026.
  • Algert Global bought 14,720 Edgewise Therapeutics shares in Q2 2026, an estimated $507K.
  • Edgewise Therapeutics made up 0.02% of Algert Global's portfolio in Q2 2026, its #841 holding.
  • Algert Global first reported a position in Edgewise Therapeutics in Q3 2024 and has held it in 6 quarters since.
  • Algert Global's Edgewise Therapeutics position peaked at $2.94M in Q4 2024.
  • 223 funds tracked by Wall St. Rank held Edgewise Therapeutics as of Q2 2026.

Based on Algert Global's 13F filing for Q2 2026, filed 13 Aug 2026.